Metastatic pancreatic cancer is still a major challenge, and evidence for that is the expectation that in the year 2030, pancreatic cancer is going to be the second leading cause of cancer death. We have to do everything in our power to try and reduce the continuing increase in the death rates in patients with metastatic pancreatic cancer. The most important consideration in doing this would be to encourage patient enrollment in clinical trials. There are no specific trials that we can mention because these drugs all have different ways of working on the cancer cell. The more patients who participate in clinical trials, the more we are going to learn about the biology of this disease. And remember that clinical trials do not take patients away from active treatment because the vast majority of clinical trials are not all based on the cytotoxic platform, which is currently gemcitabine + nab-paclitaxel or FOLFIRINOX added as an experimental agent. Therefore, patients are not going to be missing out on any active treatment, but at the same time will have the opportunity to get a new drug. Patients who go into clinical trials get excellent care, and that is something to keep in mind. Also, when we talk about a disease like pancreatic cancer, which is not as common as colorectal, breast, or prostate cancer, having access to a specialized center with the ability to do clinical trials is a plus. Not only will patients get excellent supportive care, but they will also have access to the latest treatments and advances in terms of the clinical trials. In addition, major cancer centers will have earlier phase clinical trials, which sometimes can be very interesting.